Volker Heyl

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2016 · 366 citations

Medicine, Oncology, Breast Oncology +16

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

Mastectomy trends for early-stage breast cancer: A report from the EUSOMA multi-institutional European database

Carlos A. Garcia‐Etienne, Mariano Tomatis, Joerg Heil et al. · European Journal of Cancer · 2012 · 113 citations

Medicine, Oncology, Surgery +10

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser et al. · The Lancet Oncology · 2022 · 83 citations

Medicine, Oncology, Pharmacology +17

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study

Naiba Nabieva, Tanja Fehm, Lothar Häberle et al. · European Journal of Cancer · 2018 · 49 citations

Medicine, Oncology, Pharmacology +17